Risk of low bone mineral density in patients with rheumatoid arthritis treated with biologics by unknown
RESEARCH ARTICLE Open Access
Risk of low bone mineral density in patients
with rheumatoid arthritis treated with biologics
Kengo Takahashi1,2†, Takao Setoguchi3*†, Hiroki Tawaratsumida1,2†, Yoshiya Arishima1,2, Hiroyuki Tominaga1,
Yasuhiro Ishidou4, Satoshi Nagano1, Sanae Shigemizu2, Noriko Aoki2, Masaki Akimoto2, Hideo Otsubo2,
Takemasa Matsuda2, Hironori Kakoi1, Toshihiko Izumi1, Shunsuke Nakamura1, Masahiro Yokouchi1,
Nobuhiko Sunahara2 and Setsuro Komiya1
Abstract
Background: Osteoporosis is a complication of rheumatoid arthritis (RA). We identified risk factors for osteoporosis
during treatment with biologics.
Methods: Femoral neck bone mineral density (BMD) was measured in 186 patients with biologics-treated RA.
We compared the characteristics of those with BMD ≥70 % of young adult mean (YAM) and those with BMD
<70 % of YAM, and undertook multivariable logistic regression analysis to identify risk factors for bone loss.
Results: Mean age and disease duration, the proportion of females, scores in the Modified Health Assessment
Questionnaire and history of vertebral fracture were significantly greater in the BMD <70 % of YAM group, but body
mass index (BMI) was significantly lower in the BMD <70 % of YAM group. There was no significant difference between
the groups in terms of other biomarkers of RA activity, the proportion treated with methylprednisolone, or the duration
or choice of biologics. The proportions of patients treated with anti-osteoporosis drugs and parathyroid hormone were
significantly higher in the BMD <70 % of YAM group. In the multivariable analysis, advanced age, female, longer
disease duration, history of past thoracic or lumbar vertebral fracture, higher Steinbrocker classification and lower
BMI were significant factors for BMD <70 % of YAM.
Discussion: We identified risk factors for bone loss in patients with RA treated with biologics. Before suppression
of disease activity by biologics, bone loss might already be advanced.
Conclusions: We recommend that patients with RA who possess these risk factors be considered for earlier and
more intense treatment to prevent bone loss, as well as addressing RA disease progression.
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Background
Rheumatoid arthritis (RA) is a systemic inflammatory dis-
ease that can cause local joint deformity, including erosions
of bone and narrowing of the joint space, and extra-articu-
lar symptoms, including anemia, pneumonitis and osteo-
porosis. Osteoporosis increases the risk of fracture and
causes pain and disability, impairing the quality of life of
patients with RA. High disease activity, glucocorticoid
therapy, immobility, advanced age, low body mass and
female sex are reportedly risk factors for osteoporosis in
patients with RA [1]. Inflammation is the one of the key
triggers of bone resorption and contributes to local and
generalized osteoporosis [2]. Inflammatory cytokines acti-
vate osteoclast differentiation, which resorb bone matrix.
Osteoclasts play a central role in bone resorption in RA,
orchestrated by T-lymphocytes, monocytes and fibroblasts
in the synovium of inflammatory joints, which produce
osteoclast differentiation-inducing factors. Osteoclast differ-
entiation is mainly promoted by the receptor activator of
nuclear factor-kappa B ligand (RANKL), which is up-
regulated by a large number of the inflammatory cytokines
involved in the pathogenesis of RA [2]. A better
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understanding of the pathogenesis of RA has improved
treatment of the disease, particularly the targeting of key
molecules by biologics [3–5]. Beyond the control of RA
activity, there is evidence that biologics might also have
beneficial effects on bone metabolism and bone remodeling
[6]. We examined the bone mineral density (BMD) of
patients with RA treated with biologics, and aimed to
establish which factors were associated with low BMD.
Methods
Patients
We retrospectively studied the records of 186 consecu-
tive patients with RA diagnosed using the 2010 criteria
of the American College of Rheumatology and treated at
the Japanese Red Cross Kagoshima Hospital with inflixi-
mab, adalimumab, golimumab, etanercept, tocilizumab
or abatacept according to established protocols.
BMD of the femoral neck
Bone mineral density was measured between December
2011 and December 2013 using the Discovery DXA system
(Hologic, Waltham, Massachusetts, USA). The BMD of the
femoral neck (in g/cm2) was calculated using the young
adult mean (YAM). The Japanese Society for Bone and
Mineral Research has proposed that primary osteoporosis
should be diagnosed when BMD is <80 % of YAM with evi-
dence of a fragility fracture, or when BMD is <70 % of YAM
[7–10]. The patients were divided into two groups: those with
BMD <70 % of YAM and those with BMD ≥70 % of YAM.
Demographic and disease-related data
Patients’ demographic and clinical characteristics were re-
corded from their medical records, including BMD, age, sex,
body mass index (BMI), disease duration, presence or ab-
sence of rheumatoid vasculitis [11], dose of methylpredniso-
lone, serum C-reactive protein (CRP) concentration, duration
and type of biologics administered, anti-osteoporosis drugs
used, Disease Activity Score 28-CRP (DAS28-CRP), Simpli-
fied Disease Activity Index (SDAI), Clinical Disease Activity
Index (CDAI), Modified Health Assessment Questionnaire
(MHAQ) score, the Steinbrocker criteria, and presence or
absence of previous vertebral or femoral neck fracture.
Statistical analysis
The Kolmogorov–Smirnov test was performed to exam-
ine the distribution of data, and data were evaluated using
the independent Student’s t test, Mann–Whitney U test,
Fisher’s exact test, Pearson’s chi-square test, or Kruskal–
Wallis test as appropriate, using Excel Statistics 2012 and
Excel Statistics 2015 (SSRI, Tokyo, Japan). P values <0.05
were considered statistically significant. Baseline factors
were examined by univariate analysis for the BMD ≥70 %
of YAM group. P-values <0.2 were further examined by
Spearman’s correlation coefficient to identify confounding
factors. Multivariable logistic regression analysis included
age, sex, disease duration, history of past vertebral frac-
ture, BMI, MHAQ score, Steinbrocker classification, and
duration of bDMARD use. Multiple logistic regression
was performed to select the best model for predicting risk
factors associated with a BMD <70 % of YAM using SPSS
software (Kondo Photo Process Co., Ltd., Osaka, Japan).
Ethics statement
The Ethics Committee on Clinical Research at the
Japanese Red Cross Kagoshima Hospital approved the
research protocol.
Consent statement
All patients gave written informed consent for their data
to be used in the study.
Results
Comparison of BMD <70 % of YAM and BMD ≥70 % of
YAM groups
Of the 186 patients who underwent DEXA scanning of
the femoral neck, 57 had BMD <70 % of YAM and 129
had BMD ≥70 % of YAM. Age was significantly higher in
the BMD <70 % of YAM group (median 65.0 years) than
the BMD ≥70 % of YAM group (median 58.0 years). The
proportion of women was significantly higher in the BMD
<70 % of YAM group (p = 0.008). Disease duration was
significantly longer in the BMD <70 % of YAM group.
Body mass index was significantly lower in the BMD
<70 % of YAM group (Table 1).
Association of methylprednisolone therapy on
osteoporosis
We examined whether methylprednisolone therapy influ-
enced the extent of osteoporosis. Twenty-six patients had
used methylprednisolone for >3 months in the BMD
<70 % of YAM group, compared with 52 in the BMD
≥70 % of YAM group (p = 0.52). There was also no signifi-
cant difference in the daily dose of methylprednisolone
between the groups (p = 0.65, Table 1).
Association of disease activity on osteoporosis
We assessed whether there was a relationship between the
extent of osteoporosis and biomarkers of disease activity
including serum CRP concentration, DAS28, CDAI, SDAI,
MHAQ score and the Steinbrocker classification. The
MHAQ score was significantly higher in the BMD <70 %
of YAM group (median 9) than the BMD ≥70 % of YAM
group (median 4, Table 1). The mean serum CRP concen-
tration did not differ significantly between the groups (p =
0.89). There were also no significant differences between
the groups in terms of DAS28-CRP (p = 0.49), CDAI (p =
0.54), SDAI (p = 0.58, Table 1) or Steinbrocker classifica-
tion (p = 0.11, Table 2).
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History of vertebral and femoral neck fractures
Seventeen patients in the BMD <70 % of YAM group
had sustained thoracic or lumbar vertebral fracture,
compared with nine in the BMD ≥70 % of YAM group
(p < 0.001), but there was no significant difference in the
number of patients who had sustained proximal femoral
fracture (p = 0.09, Table 1).
Association of disease activity on osteoporosis of
duration or type of biologics therapy on osteoporosis
The duration of biologics therapy did not differ signifi-
cantly between the groups (p = 0.166, Table 1). We clas-
sified biologics into: tumor necrosis factor-α (TNFα)
inhibitors (infliximab, adalimumab, golimumab and eta-
nercept); tocilizumab; abatacept; and switch biologics
(where TNFα inhibitor therapy was switched to toci-
lizumab or abatacept). There was no significant differ-
ence in biologics class between the BMD <70 % of YAM
and BMD ≥70 % of YAM groups (p = 0.67, Table 3).
Association of disease activity on osteoporosis of
duration or type of biologics therapy on osteoporosis of
anti-osteoporosis drug therapy on osteoporosis
The proportion of patients treated with anti-osteoporosis
drugs was significantly higher in the BMD <70 % of YAM
group (p = 0.004, Table 4). Having divided the anti-
osteoporosis drugs into bisphosphonates, parathyroid
hormone (PTH) and others (such as vitamin D and ral-
oxifene), we found that the proportion of patients treated
with PTH was significantly higher in the BMD <70 % of
YAM group (p = 0.008, Table 5).
Multiple logistic regression analysis of factors associated
with BMD <70 % of YAM
We performed univariate analysis (Additional file 1:
Table S1) and multiple logistic regression analysis of fac-
tors associated with a BMD <70 % of YAM. Spearman’s
correlation coefficient revealed no high relationships
between a BMD <70 % of YAM and age, sex, disease
duration, history of vertebral fracture, BMI, MHAQ,
Table 1 Demographic and clinical characteristics of the BMD <70 % of YAM and BMD ≥70 % of YAM groups
BMD <70 % of YAM BMD ≥70 % of YAM p value
Age 65.0 (58.0–69.0) 58.0 (53.0–66.0) 0.0044*
Proportion female 93.0 % 77.9 % 0.0079*
Disease duration (year) 15.0 (8.0–20.0) 8.0 (4.0–15.0) 0.0004*
BMI 21.4 ± 2.8 23.6 ± 3.3 <0.0001*
Rate of rheumatoid vasculitis 1.8 % 1.6 % 0.67
Proportion taking methylprednisolone 45.6 % 40.3 % 0.52
Dose of methylprednisolone (mg) 2.0 (1.0–3.5) 3.3 (2.0–6.0) 0.65
CRP (mg/dL) 0.09 (0.03–0.31) 0.08 (0.03–0.37) 0.89
DAS28-CRP 2.63 (1.88–3.38) 2.50 (1.70–3.30) 0.49
CDAI 6.70 (2.90–14.90) 5.80 (2.60–12.95) 0.54
SDAI 6.95 (3.05–14.10) 6.30 (2.74–12.94) 0.58
MHAQ score 9.00 (1.00–14.00) 4.00 (0.00–8.00) 0.002*
History of proximal femoral fracture 2/57 0/129 0.087
History of thoracic or lumbar vertebral fracture 17/57 9/129 <0.001*
Duration of biologics therapy 4.2 ± 2.6 3.6 ± 2.3 0.166
BMD bone mineral density, YAM young adult mean, BMI body mass index, CRP serum C-reactive protein concentration, DAS28-CRP Disease Activity Score-28-CRP,
SDAI Simplified Disease Activity Index, CDAI Clinical Disease Activity Index, MHAQ Modified Health Assessment Questionnaire
Table 2 Classification of patients according to the Steinbrocker
criteria in the BMD <70 % of YAM and BMD ≥70 % of YAM
groups








BMD bone mineral density, YAM young adult mean
Table 3 Class of biologics taken in the BMD <70 % of YAM and
BMD ≥70 % of YAM groups
BMD <70 % of YAM BMD ≥70 % of YAM
TNFα inhibitor 26 66
Tocilizumab 6 16
Abatacept 3 9
Switch biologics 22 38
(p = 0.67)
BMD bone mineral density, YAM young adult mean, TNFα tumor
necrosis factor-α
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Steinbrocker classification, or duration of biologics use.
Multiple logistic regression analysis showed that age
(odds ratio [OR] 1.065), female (OR 5.019), disease dur-
ation (OR 1.077), history of vertebral fracture (OR
7.708), and Steinbrocker classification (OR 2.302) were
associated with a greater risk of a BMD <70 % of YAM,
whereas higher BMI (OR 0.766) reduced the risk for a
BMD <70 % of YAM (Table 6).
Discussion
The Japanese Society for Bone and Mineral Research
proposed revised diagnostic criteria for primary osteo-
porosis in 2012. Primary osteoporosis is diagnosed when
BMD is <80 % of YAM with evidence of a fragility frac-
ture, or <70 % of YAM [7–9]. We therefore elected to
identify risk factors for a BMD <70 % of YAM.
Although the presence of osteoporosis, as identified by
DEXA, is the best predictor of fracture in patients with
RA [12], many indices of risk have been reported to
identify low BMD, including the Simple Calculated Osteo-
porosis Risk Estimation (SCORE), the Osteoporosis Risk
Assessment Instrument (ORAI), the Osteoporosis Self-
Assessment Tool, the Osteoporosis Index of Risk (OSIRIS)
and the Fracture Risk Assessment Tool (FRAX). Although
these indices have substantial sensitivity in populations not
affected by RA, they do not satisfactorily predict low BMD
in RA [13]. We showed that age, female sex, disease dur-
ation, history of vertebral fracture, Steinbrocker classifica-
tion, and lower BMI were associated with a greater risk of
bone loss in patients with RA treated by biologics. There is
still substantial debate about the risk factors for osteopor-
osis in patients with RA. The erythrocyte sedimentation
rate, DAS, corticosteroid therapy, anti-resorptive osteopor-
osis treatment, MHAQ score, swollen joint count, tender
joint count, hormone replacement therapy, disease severity,
BMI, immobilization, and disease duration have all been
implicated [14–18]. Disease duration and disease activity
has been considered the most important risk factors for
osteoporosis [2, 19, 20]. Although our risk factors were
found in patients with RA treated with biologics, these risk
factors are compatible with those in the general population
[21–23]. We also found that methylprednisolone therapy,
serum CRP concentration, DAS28-CRP, CDAI and SDAI
were not risk factors for low BMD. These discrepancies
may be a consequence of treatment with biologics. Before
suppression of disease activity by biologics, bone loss might
already be advanced. Bone loss is often found in patients
with recent-onset RA [24] and bone loss has reportedly
already started during the autoimmune phase of RA, long
before inflammation occurs [25], implying that therapy for
osteoporosis should be initiated promptly. Further research
will be needed to establish whether these factors could be
used prospectively as predictors of osteoporosis and frac-
ture in patients with RA. We found only one English-
language paper in PubMed that showed the relationship
between the Steinbrocker classification and bone loss in
patients with RA. The article reported that a higher Stein-
brocker classification is a risk factor for bone loss of the
femoral neck and lumbar spine [26]. Our findings are
compatible with this report.
As well as influencing disease activity, biologics may
prevent bone loss via a direct effect on bone metabolism.
It is well recognized that TNFα induces differentiation
of osteoclast precursors through a synergistic action
with RANKL [27]. Bone metabolism and remodeling are
regulated by a balance between TNF superfamily mole-
cules, RANKL, osteoprotegerin, osteoclastogenesis in-
hibitory factor and TNF-related apoptosis-inducing
ligand [12, 28, 29]. These cytokines are responsible for
the imbalance between bone resorption and formation
in RA, which may explain the ability of biologics not
only to suppress systemic inflammation, but also to
prevent bone loss [30–33]. Nonetheless, there appears to
Table 4 Use of anti-osteoporosis drugs in the BMD <70 % of
YAM and BMD ≥70 % of YAM groups






BMD bone mineral density, YAM young adult mean
Table 5 Type of anti-osteoporosis drugs used in the BMD
<70 % of YAM and BMD ≥70 % of YAM groups
BMD <70 % of YAM BMD ≥70 % of YAM p value
Bisphosphonate 30 54 0.087
PTH 4 1 0.008*
Others 10 16 0.351
BMD bone mineral density, YAM young adult mean
Table 6 Multiple logistic regression analysis of factors
associated with bone mineral density <70 % of young adult
mean
Feature Odds ratio 95 % confidence
intervals
p value
Age (per 1 year increase) 1.065 1.015–1.101 0.003*
sex 5.019 1.367–18.43 0.015*
Disease duration (per 1 year
increase)
1.077 1.028–1.128 0.002*
History of past vertebral
fracture
7.708 2.505–23.72 <0.001*
BMI (per 1 point increase) 0.766 0.665–0.883 <0.001*
Steinbrocker classification 2.302 1.473–3.597 <0.001*
BMD bone mineral density, BMI body mass index
Takahashi et al. BMC Musculoskeletal Disorders  (2015) 16:269 Page 4 of 6
be no significant difference in BMD change in biologics
responders and non-responders [34, 35]. In addition, we
found that the class and duration of biologics therapy
was not significantly different in the BMD <70 % of
YAM and BMD ≥70 % of YAM groups. Sequential
evaluation of BMD during biologics therapy should help
to illuminate their influence on bone density.
Although the proportion of patients treated with
anti-osteoporosis drugs was significantly higher in the
BMD <70 % of YAM group, bone loss could not be
completely prevented. In addition, the proportion of
patients treated with PTH was significantly higher in
the BMD <70 % of YAM group, even though the abso-
lute number of patients was only four. These findings
suggest that patients who possess the risk factors that
we have identified require earlier and more intensive
treatment to prevent bone loss.
Our study has some limitations. First, data collection
was retrospective. Second, BMD was measured once in
each patient, so longitudinal data are not available.
Third, we did not measure the change in biomarkers of
bone remodeling in the blood or urine. Although there
is reportedly no change in the indices of bone remodel-
ing after 1 year of biologics treatment [30, 35], we are
now examining longitudinal changes in BMD and bio-
markers of bone turnover in a prospective study.
Conclusions
We identified risk factors for bone loss in patients with
RA treated with biologics. As fragility bone fracture may
substantially impair quality of life, and also has substan-
tial adverse socioeconomic consequences, our findings
suggest that osteoporosis should be detected and ad-
dressed promptly in patients with bDMARD-treated RA
who possess these risk factors.
Additional file
Additional file 1: Table S1. Univariate analysis of factors potentially
associated with low bone mineral density in patients with rheumatoid
arthritis treated with biologics. (DOCX 14 kb)
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